Details

Autor(en) / Beteiligte

• Malhotra, Atul
• Thebaud, Bernard
• Paton, Madison C. B.
• Fleiss, Bobbi
• Papagianis, Paris
• Baker, Elizabeth
• Bennet, Laura
• Yawno, Tamara
• Elwood, Ngaire
• Campbell, Belinda
• Chand, Kirat
• Zhou, Lindsay
• Penny, Tayla
• Nguyen, Timothy
• Pepe, Salvatore
• Gunn, Alistair J.
• McDonald, Courtney A.

Titel

Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022)

Ist Teil von

• Pediatric research, 2023-11, Vol.94 (5), p.1631-1638

Ort / Verlag

New York: Nature Publishing Group US

Erscheinungsjahr

2023

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Despite considerable advances, there is a need to improve the outcomes of newborn infants, especially related to prematurity, encephalopathy and other conditions. In principle, cell therapies have the potential to protect, repair, or sometimes regenerate vital tissues; and improve or sustain organ function. In this review, we present highlights from the First Neonatal Cell Therapies Symposium (2022). Cells tested in preclinical and clinical studies include mesenchymal stromal cells from various sources, umbilical cord blood and cord tissue derived cells, and placental tissue and membrane derived cells. Overall, most preclinical studies suggest potential for benefit, but many of the cells tested were not adequately defined, and the optimal cell type, timing, frequency, cell dose or the most effective protocols for the targeted conditions is not known. There is as yet no clinical evidence for benefit, but several early phase clinical trials are now assessing safety in newborn babies. We discuss parental perspectives on their involvement in these trials, and lessons learnt from previous translational work of promising neonatal therapies. Finally, we make a call to the many research groups around the world working in this exciting yet complex field, to work together to make substantial and timely progress to address the knowledge gaps and move the field forward. Impact Survival of preterm and sick newborn infants is improving, but they continue to be at high risk of many systemic and organ-specific complications. Cell therapies show promising results in preclinical models of various neonatal conditions and early phase clinical trials have been completed or underway. Progress on the potential utility of cell therapies for neonatal conditions, parental perspectives and translational aspects are discussed in this paper.